NASDAQ:ACXP

Acurx Pharmaceuticals (ACXP) Stock Forecast, Price & News

$1.41

-0.09 (-6.00%)

(As of 09/27/2023 ET)

Compare

Today's Range: $1.35
▼
$1.50
50-Day Range: $1.41
▼
$2.22
52-Week Range: $1.35
▼
$4.61

Volume: 44,419 shs
Average Volume: 31,582 shs
Market Capitalization: $18.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.00

Acurx Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 822.0% Upside
$13.00 Price Target
Short Interest: Healthy
0.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.43
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.08) to ($0.82) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

199th out of 976 stocks

Pharmaceutical Preparations Industry

74th out of 453 stocks

3.5

Analyst's Opinion

Consensus Rating
Acurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.00, Acurx Pharmaceuticals has a forecasted upside of 822.0% from its current price of $1.41.
Amount of Analyst Coverage
Acurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.06% of the float of Acurx Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Acurx Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Acurx Pharmaceuticals has recently decreased by 51.09%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Acurx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Acurx Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACXP.

3.6

News and Social Media Coverage

News Sentiment
Acurx Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Acurx Pharmaceuticals this week, compared to 0 articles on an average week.
MarketBeat Follows
1 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
35.30% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.28% of the stock of Acurx Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Acurx Pharmaceuticals are expected to grow in the coming year, from ($1.08) to ($0.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Acurx Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acurx Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Acurx Pharmaceuticals has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Acurx Pharmaceuticals (NASDAQ:ACXP) Stock

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.

ACXP Price History

30 days | 90 days | 365 days | Advanced Chart

ACXP Stock News Headlines

September 13, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)

August 22, 2023 | finance.yahoo.com

Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023

September 28, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

August 15, 2023 | msn.com

HC Wainwright & Co. Maintains Acurx Pharmaceuticals (ACXP) Buy Recommendation

August 15, 2023 | markets.businessinsider.com

Maxim Group Remains a Buy on Acurx Pharmaceuticals (ACXP)

August 15, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Acurx Pharmaceuticals (ACXP)

August 14, 2023 | markets.businessinsider.com

Acurx Pharma's Phase 2b Study Of Ibezapolstat In C. Difficile Infection On Track

July 24, 2023 | finance.yahoo.com

Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update

September 28, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

June 20, 2023 | finance.yahoo.com

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023

June 15, 2023 | finance.yahoo.com

Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET

May 17, 2023 | insidermonkey.com

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2023 Earnings Call Transcript

May 16, 2023 | finance.yahoo.com

Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering

May 15, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Acurx Pharmaceuticals (ACXP)

May 12, 2023 | msn.com

Recap: Acurx Pharmaceuticals Q1 Earnings

May 12, 2023 | finance.yahoo.com

Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update

May 11, 2023 | msn.com

A Preview Of Acurx Pharmaceuticals's Earnings

May 5, 2023 | finance.yahoo.com

Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update

April 22, 2023 | finance.yahoo.com

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

April 19, 2023 | finance.yahoo.com

Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference

April 12, 2023 | msn.com

HC Wainwright & Co. Reiterates Acurx Pharmaceuticals (ACXP) Buy Recommendation

April 11, 2023 | finance.yahoo.com

FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference

March 23, 2023 | benzinga.com

Acurx Pharmaceuticals Earns Bullish Update From H.C. Wainwright & Co., Affirms BUY Rating And $14 Price Target

March 19, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and Acurx Pharmaceuticals (ACXP)

March 18, 2023 | seekingalpha.com

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Call Transcript

March 18, 2023 | finance.yahoo.com

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2022 Earnings Call Transcript

March 16, 2023 | msn.com

Acurx Pharmaceuticals GAAP EPS of -$0.28 beats by $0.15

See More Headlines

Receive ACXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACXP Company Calendar

Last Earnings: 8/14/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACXP
CUSIP: N/A
CIK: 1736243
Web: www.acurxpharma.com
Phone: 917-533-1469
Fax: N/A
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.00
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +815.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,090,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -183.90%
Return on Assets: -142.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.06
Quick Ratio: 3.06

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.63 per share
Price / Book: 2.25

Miscellaneous

Outstanding Shares: 13,010,000
Free Float: 8,414,000
Market Cap: $18.47 million
Optionable: Not Optionable
Beta: -1.00

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Robert J. DeLuccia (Age 77)
Co-Founder & Exec. Chairman
Comp: $677.19k

Mr. David P. Luci CPA (Age 56)
CPA, Esq., J.D., Co-Founder, Pres, CEO, Corp. Sec. & Director
Comp: $655k

Mr. Robert G. Shawah CPA (Age 56)
CPA, Co-Founder & CFO
Comp: $375k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ACXP Stock - Frequently Asked Questions

Should I buy or sell Acurx Pharmaceuticals stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACXP shares.
View ACXP analyst ratings or view top-rated stocks.
What is Acurx Pharmaceuticals' stock price forecast for 2023?: 2 Wall Street analysts have issued 1-year target prices for Acurx Pharmaceuticals' shares. Their ACXP share price forecasts range from $13.00 to $13.00. On average, they expect the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 815.5% from the stock's current price.
View analysts price targets for ACXP or view top-rated stocks among Wall Street analysts.
How have ACXP shares performed in 2023?: Acurx Pharmaceuticals' stock was trading at $3.98 at the beginning of the year. Since then, ACXP shares have decreased by 64.3% and is now trading at $1.42.
View the best growth stocks for 2023 here.
Are investors shorting Acurx Pharmaceuticals?: Acurx Pharmaceuticals saw a drop in short interest during the month of September. As of September 15th, there was short interest totaling 6,700 shares, a drop of 51.1% from the August 31st total of 13,700 shares. Based on an average trading volume of 35,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the company's shares are short sold.
View Acurx Pharmaceuticals' Short Interest.
When is Acurx Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ACXP earnings forecast.
How were Acurx Pharmaceuticals' earnings last quarter?: Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. During the same period last year, the company earned ($0.26) earnings per share.

When did Acurx Pharmaceuticals IPO?: (ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO.
What is Acurx Pharmaceuticals' stock symbol?: Acurx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACXP."
Who are Acurx Pharmaceuticals' major shareholders?: Acurx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Osaic Holdings Inc. (0.17%), Osaic Holdings Inc. (0.17%) and One68 Global Capital LLC (0.10%). Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia.
View institutional ownership trends.
How do I buy shares of Acurx Pharmaceuticals?: Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Acurx Pharmaceuticals' stock price today?: One share of ACXP stock can currently be purchased for approximately $1.42.
How much money does Acurx Pharmaceuticals make?: Acurx Pharmaceuticals (NASDAQ:ACXP) has a market capitalization of $18.47 million. The company earns $-12,090,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.
How can I contact Acurx Pharmaceuticals?: The official website for the company is www.acurxpharma.com. The company can be reached via phone at 917-533-1469 or via email at davidluci@acurxpharma.com.

This page (NASDAQ:ACXP) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial